KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Receivables (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Change in Receivables for 13 consecutive years, with $129000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 83.9% to $129000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, down 317.22% year-over-year, with the annual reading at -$1.4 million for FY2025, 317.22% down from the prior year.
  • Change in Receivables hit $129000.0 in Q4 2025 for Arbutus Biopharma, up from -$120000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.3 million in Q1 2023 to a low of -$1.2 million in Q1 2025.
  • Historically, Change in Receivables has averaged -$13900.0 across 5 years, with a median of -$85000.0 in 2023.
  • Biggest five-year swings in Change in Receivables: soared 1890.91% in 2022 and later crashed 644.0% in 2024.
  • Year by year, Change in Receivables stood at -$768000.0 in 2021, then skyrocketed by 37.11% to -$483000.0 in 2022, then increased by 18.22% to -$395000.0 in 2023, then skyrocketed by 302.78% to $801000.0 in 2024, then crashed by 83.9% to $129000.0 in 2025.
  • Business Quant data shows Change in Receivables for ABUS at $129000.0 in Q4 2025, -$120000.0 in Q3 2025, and -$157000.0 in Q2 2025.